Dengue Virus
15
0
0
13
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 15 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
62%
8 of 13 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 13 completed trials
Clinical Trials (15)
Safety and Immunogenicity of Three V181 Dengue Vaccine Potencies in Adults (V181-003)
Serological Measurement of Montpellier Professionals' Contacts with Infectious Agents Responsible for Animal-borne Diseases
Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years
Efficacy and Safety of Dengue Vaccine in Healthy Children
Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects
Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America
Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore
Comparison of Tetravalent Dengue Virus Purified Inactivated Vaccine and Tetravalent Dengue Virus Live Attenuated Vaccine
Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US
Zika Virus and Related Arbovirus Infections in Deferred Blood Donors (ZVADD)
A Prospective, Open Label, Treatment Use Study of Patient Safety Following Transfusion of INTERCEPT Platelet Components
Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects
Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults
Safety and Immune Response to an Investigational Dengue Type 2 Vaccine
Evaluation of the Safety and Immune Response to an Investigational Dengue Type 1 Vaccine